Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 1

Conditions

Polycystic Ovary Syndrome 2Hyperandrogenism 2Glioblastoma 1

Interventions

pembrolizumab 1262Specimen Handling 924Magnetic Resonance Spectroscopy 829Carboplatin 821Cyclophosphamide 799Cisplatin 722Nivolumab 667Paclitaxel 627Radiotherapy 608Gemcitabine 570Biopsy 557Bevacizumab 478Dexamethasone 437fludarabine 407Docetaxel 377venetoclax 367Oxaliplatin 364Capecitabine 355Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 329Drug Therapy 325Doxorubicin 316Radiosurgery 314Standard of Care 309Blood Specimen Collection 308Pemetrexed 304Ipilimumab 298Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Spironolactone × 1 year × Clear all
NCT07431216 2026-03-30

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression

Starlight Therapeutics Inc.

Phase 1/2 Not yet recruiting
68 enrolled
CNS

Glioblastoma

NCT03068910 2025-08-05

CRM008

University of Virginia

Phase EARLY_PHASE1 Recruiting
32 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

NCT04723862 2025-08-05

CBS010

University of Virginia

Phase EARLY_PHASE1 Recruiting
32 enrolled

Polycystic Ovary Syndrome, Hyperandrogenism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡